Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine.
Levin MK, Wang K, Yelensky R, Cao Y, Ramos C, Hoke N, Pippen J Jr, Blum JL, Brooks B, Palmer G, Palma N, Balasubramanian S, Ross JS, O'Shaughnessy J. Levin MK, et al. Among authors: yelensky r. Cancer Med. 2015 Aug;4(8):1289-93. doi: 10.1002/cam4.464. Epub 2015 Apr 13. Cancer Med. 2015. PMID: 25871911 Free PMC article.
Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
Ross JS, Wang K, Khaira D, Ali SM, Fisher HA, Mian B, Nazeer T, Elvin JA, Palma N, Yelensky R, Lipson D, Miller VA, Stephens PJ, Subbiah V, Pal SK. Ross JS, et al. Among authors: yelensky r. Cancer. 2016 Mar 1;122(5):702-11. doi: 10.1002/cncr.29826. Epub 2015 Dec 9. Cancer. 2016. PMID: 26651075 Free article.
Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ. Ross JS, et al. Among authors: yelensky r. Cancer. 2016 Sep 1;122(17):2654-62. doi: 10.1002/cncr.30102. Epub 2016 Jun 10. Cancer. 2016. PMID: 27284958 Free article.
Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
Ross JS, Wang K, Sheehan CE, Boguniewicz AB, Otto G, Downing SR, Sun J, He J, Curran JA, Ali S, Yelensky R, Lipson D, Palmer G, Miller VA, Stephens PJ. Ross JS, et al. Among authors: yelensky r. Clin Cancer Res. 2013 May 15;19(10):2668-76. doi: 10.1158/1078-0432.CCR-13-0295. Epub 2013 Apr 10. Clin Cancer Res. 2013. PMID: 23575477
Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.
Ross JS, Wang K, Al-Rohil RN, Nazeer T, Sheehan CE, Otto GA, He J, Palmer G, Yelensky R, Lipson D, Ali S, Balasubramanian S, Curran JA, Garcia L, Mahoney K, Downing SR, Hawryluk M, Miller VA, Stephens PJ. Ross JS, et al. Among authors: yelensky r. Mod Pathol. 2014 Feb;27(2):271-80. doi: 10.1038/modpathol.2013.135. Epub 2013 Jul 26. Mod Pathol. 2014. PMID: 23887298 Free article.
Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
Young G, Wang K, He J, Otto G, Hawryluk M, Zwirco Z, Brennan T, Nahas M, Donahue A, Yelensky R, Lipson D, Sheehan CE, Boguniewicz AB, Stephens PJ, Miller VA, Ross JS. Young G, et al. Among authors: yelensky r. Cancer Cytopathol. 2013 Dec;121(12):688-94. doi: 10.1002/cncy.21338. Epub 2013 Jul 24. Cancer Cytopathol. 2013. PMID: 23893923 Free article.
A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
Ross JS, Wang K, Gay LM, Al-Rohil RN, Nazeer T, Sheehan CE, Jennings TA, Otto GA, Donahue A, He J, Palmer G, Ali S, Nahas M, Young G, Labrecque E, Frampton G, Erlich R, Curran JA, Brennan K, Downing SR, Yelensky R, Lipson D, Hawryluk M, Miller VA, Stephens PJ. Ross JS, et al. Among authors: yelensky r. Clin Cancer Res. 2014 Jan 1;20(1):68-75. doi: 10.1158/1078-0432.CCR-13-1992. Epub 2013 Nov 5. Clin Cancer Res. 2014. PMID: 24192927
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Balko JM, et al. Among authors: yelensky r. Cancer Discov. 2014 Feb;4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286. Epub 2013 Dec 19. Cancer Discov. 2014. PMID: 24356096 Free PMC article.
Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.
Ross JS, Wang K, Rand JV, Sheehan CE, Jennings TA, Al-Rohil RN, Otto GA, Curran JC, Palmer G, Downing SR, Yelensky R, Lipson D, Balasubramanian S, Garcia L, Mahoney K, Ali SM, Miller VA, Stephens PJ. Ross JS, et al. Among authors: yelensky r. Am J Surg Pathol. 2014 Feb;38(2):235-8. doi: 10.1097/PAS.0000000000000102. Am J Surg Pathol. 2014. PMID: 24418857
Concordance of genomic alterations between primary and recurrent breast cancer.
Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM. Meric-Bernstam F, et al. Among authors: yelensky r. Mol Cancer Ther. 2014 May;13(5):1382-9. doi: 10.1158/1535-7163.MCT-13-0482. Epub 2014 Mar 7. Mol Cancer Ther. 2014. PMID: 24608573 Free PMC article.
84 results